Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 16/20 | 0.51 |
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | ELOC | Q15369 | 3/20 | 0.41 |
| ▸ | ELOB | Q15370 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30149065 | 0.90 | VHL (0.52) | VHLDPP4DPP7ELOCELOB | |
| SCHEMBL24757855 | 0.90 | VHL (0.52) | VHLDPP4DPP7ELOCELOB | |
| SCHEMBL30772007 | 0.90 | VHL (0.44) | VHLDPP4DPP7ELOCELOB | |
| SCHEMBL30771993 | 0.89 | VHL (0.51) | VHLDPP4DPP7ELOCELOB | |
| SCHEMBL30772055 | 0.89 | VHL (0.51) | VHLDPP4DPP7ELOCELOB | |
| SCHEMBL30771987 | 0.89 | VHL (0.51) | VHLDPP4DPP7ELOCELOB | |
| SCHEMBL24757713 | 0.89 | VHL (0.51) | VHLDPP4ELOCELOBDPP8 | |
| SCHEMBL27359490 | 0.88 | VHL (0.44) | VHLDPP4ELOCELOB | |
| SCHEMBL30772026 | 0.87 | VHL (0.49) | VHLDPP4ELOCELOBDPP8 | |
| SCHEMBL25166783 | 0.87 | VHL (0.52) | VHLDPP4ELOCELOBDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293558-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. | 2024-09-05 | — | — | US | disclosed |
| WO-2024001839-A1 | HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| WO-2022266206-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293558-A1 | KRAS INHIBITOR CONJUGATES | KRAS, MDM2, NRAS | VHL 5/4885DPP4 3723/4885DPP7 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.